1/4 eGFR slope is now a common outcome in #IgAN trials and KDIGO has proposed a treatment target of <1 mL/min/1.73m²/year decline. We asked: could we predict a patient’s future eGFR slope to identify risk of progression earlier? journals.sagepub.com/doi/10.1177/...

Challenges in Predicting Estimated Glomerular Filtration Rate Slope Among Adult Patients With IgA Nephropathy: A Population-Based Cohort Study - Bryce Barr, Mark Canney, Navdeep Tangri, Lisa M. Lix, 2...

Background Traditional epidemiologic studies and clinical trials in IgA nephropathy (IgAN) have focused on kidney failure or large declines in estimated glomeru...

journals.sagepub.com

1/5 There has been a major shift in how we treat IgA nephropathy. New studies have shown that kidney failure risk begins at lower levels of proteinuria than previously appreciated, and multiple trials have demonstrated that targeted therapies can reduce the risk of progression.

ASN Publications@asnpublications.bsky.social · 4mo ago

Why does your IgA nephropathy care depend on who you see? In a Manitoba study published in #ASNKidney360, doctors drove 31% of variability in biopsy timing and 7% in steroid use. kidney.pub/KID1232 Bryce Barr

No Here’s @adnan-sharif.bsky.social making an eloquent case youtu.be/4l_1j24CdOg?... The best treatment for CAD in a dialysis patient is a kidney transplant

The Topsy-Turvy approach to CVD in Kidney Transplant with Prof Adnan Sharif

YouTube video by Ottawa Nephrology

youtu.be

#NephSky as a non-transplanter who watches patients wait months-years on dialysis for testing that is known to be unhelpful for perioperative risk reduction in the general population, is there any good justification for screening patients for CAD pre-transplant?

ASN Publications@asnpublications.bsky.social · 10mo ago

Coronary artery disease is a barrier to kidney transplantation. This new meta-analysis in #ASNJASN investigates how many patients meet class 1 indication for revascularization. Read more: kidney.pub/JASN0890 @qandeelsoomro.bsky.social

A little retrospective can be helpful at times to work out what has been happening and what was knowable. Let's travel back in time to 2017 (~8 years ago) when I was lead author on a paper about the post-truth world. doi.org/10.1016/j.ja... 1/6

This post is written in such an irresponsible way. He is not “determined to challenge scientific orthodoxy.” He is a moron, who knows nothing about the portfolio he oversees, who is forcing the CDC to publish blatantly false information, the consequence of which will be the death of many children.

The New York Times@nytimes.com · 11mo ago

Breaking News: Robert F. Kennedy Jr. said he personally instructed the CDC to abandon its position that vaccines do not cause autism. The move underscores his determination to challenge scientific orthodoxy — in this case, that vaccines save lives — and bend the health department to his will.

It was a pleasure to collaborate with @kronbichlerlab.bsky.social and Dr. Astrid Weins on this article. We describe transformations in our understanding of podocytopathies, and novel treatment approaches in light of those advancements. journals.lww.com/co-nephrolhy...

New insights into the biology and treatment of minimal... : Current Opinion in Nephrology and Hypertension

sease and focal segmental glomerulosclerosis, there has been a transformation of our understanding of disease pathogenesis and treatment rationale. Recent findings Antinephrin antibodies are common...

journals.lww.com

“Those nasty Canadians are ripping us off and are controlled by Mexican cartels. They’re poisoning us with fentanyl and need to become the 51st state or they will pay a high price” is a belief that literally ZERO Americans had six weeks ago. It’s entirely invented from scratch.

#askrenal Any tips for getting patients started on GLP-1 without debilitating nausea? Starting patients as per the FLOW protocol, counseling them that it could be temporary and to try to keep going, and I’ve only got a few still on treatment. What am I doing wrong? @hswapnil.medsky.social

Feels like my first 🦋post should be about lupus, but it’s not too late to register for this CSN Webinar about IgA! I’ll be discussing the all of the recent data, interpreting new trial endpoints, and how to apply the available treatments in Canada through a practical lens! www.csncommunity.ca